https://www.avient.com/sites/default/files/2022-03/CESA Nox Product Selector Guide.pdf
Avient makes no warranties or
guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
CESA NOX – STANDARD OFFERINGS
CESA Nox additives can be used in combination with other CESA masterbatches, and formulations can be customized for most applications.
Some formulations are specific for use in U.S. and Canada.
https://www.avient.com/sites/default/files/2022-03/CESA Release Product Selector Guide.pdf
Some formulations are specific for use in U.S. and Canada.
Avient makes no warranties or
guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
You have the responsibility to conduct full-scale end-product performance testing
to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.
https://www.avient.com/sites/default/files/2022-03/CESA Extend Product Selector Guide.pdf
Some formulations are specific for use in U.S. and Canada.
Avient makes no warranties or
guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
You have the responsibility to conduct full-scale end-product performance testing
to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.
https://www.avient.com/sites/default/files/2023-07/Versaflex HC _ Versaflex HC BIO - BT Series Product Overview.pdf
Versaflex™ HC and Versaflex™ HC BIO
Thermoplastic Elastomers
TPEs for Biopharmaceutical Tubing (BT)
The Versaflex™ HC and Versaflex™ HC BIO BT series is
formulated specifically to handle the complexities
of biopharma tubing.
Avient makes no warranties or
guarantees respecting suitability of either Avient’s products or the information for your process or end-use application.
You have the responsibility to conduct full-scale end-product performance testing
to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.
https://www.avient.com/sites/default/files/resources/PolyOne%2520IR%2520Presentation%2520Sidoti%2520wNonGAAP%2520Rec.pdf
Factors that could cause actual results to differ materially from those implied by these forward looking statements include but are not limited to:• Factors that could cause actual results to differ materially from those implied by these forward‐looking statements include, but are not limited to:
Our ability to achieve the strategic and other objectives relating to the Spartech acquisition, including any expected synergies; our ability to successfully
integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive;
Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and
cost of credit in the future;
The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate
liquidity) to maintain their credit availability;liquidity) to maintain their credit availability;
The speed and extent of an economic recovery, including the recovery of the housing market;
Our ability to achieve new business gains;
The amount and timing of repurchases, if any, of PolyOne common shares and our ability to pay regular quarterly cash dividends and the amounts and
timing of any future dividends;
The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks;
Changes in polymer consumption growth rates in the markets where we conduct business;g p y p g ;
Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online;
Fluctuations in raw material prices, quality and supply and in energy prices and supply;
Production outages or material costs associated with scheduled or unscheduled maintenance programs;
Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters;
An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital
reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services;, , p y p y g , y p p ;
An inability to maintain appropriate relations with unions and employees; and
Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and
changes in the rate of inflation.
• The above list of factors is not exhaustive.
• We undertake no obligation to publicly update forward‐looking statements, whether as a result of new information, future events or otherwise.
Page 3
Strategy and Execution Drive Results
90%
$22
$24
PolyOne
Stock Price
50%
$18
$20
$22
S&P 500 (relative performance)
30%
$12
$14
$16
S&P 500 (relative performance)
‐10%
10%
$6
$8
$10
50%
‐30%
$0
$2
$4
$
|
‐50%$0
2006 2007 2008 2009 2010 2011 2012 2013
Page 4
Four Pillar Strategy
The World’s Premier Provider of SpecializedThe World s Premier Provider of Specialized
Polymer Materials, Services & Solutions
Page 5
Spartech – Compelling Strategic Rationale
• Spartech expands PolyOne’s specialty portfolio with adjacent
technologies in attractive end markets
Bolt on acquisition with opportunity for global expansion as only Bolt‐on acquisition with opportunity for global expansion, as only
6% of Spartech’s revenues are outside of North America
• PolyOne has a proven management team with a track record of
transformational success
• Preliminary synergy estimated at $65 million run rate by end of
3year 3
Significant opportunity to expand profitability by leveraging
PolyOne’s four pillar strategy
• Substantial potential share price appreciation for all
shareholders
f f ll / $ Accretive to EPS in first full year post‐acquisition / $0.50 once
synergies realized
Page 6
Mix Shift Highlights Specialty Transformation
Old
PolyOne Transformation
100%
2015
Target
80%
In
co
m
e*
65 – 75%40%
60%
f O
pe
ra
tin
g
34% 43% 45%
65 75%
20%
o
f
2%0%
2005 2008 2010 2012 2015
Specialty OI $5M $46M $87M $114M Target
*Operating Income excludes corporate charges and special items
JV's PP&S Distribution Specialty
Page 7
Proof of Performance
2007 2012 2015
“Where we were” “Where we are” “Where we Where we were Where we are expect to be"
1) Operating Income %
Specialty 3.2% 9.1% 12 – 16%
PP&S 6.1% 9.0% 9 – 12%
Distribution 3.0% 6.4% 6 – 7.5%
2) Specialty Platform
sss% of Operating Income 20% 45% 65 – 75%
3) ROIC* ( ft t ) 7% 11% 15%3) ROIC* (after‐tax) 7% 11% 15%
4) Adjusted EPS Growth** N/A 4 yr CAGR = 55% Double Digit
Expansion
*ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period
**4 yr EPS CAGR calculated using 2012 adjusted EPS vs 2008 adjusted EPS
Page 8
Proof of Performance
Spartech Opportunity
Intermediate
PolyOne Spartech Opportunity
2006 2012 Today Goal
“Where we
were”
“Where we
are”
“Where
Spartech is”*
“Where we
can go”were are Spartech is can go
Specialty
Operating
Margin
1.5% 9.1% 2.2% 8.0% – 10.0%
Margin
Page 9
*Pro Forma results include Spartech corporate allocations for FY12 ended November 3, 2012
PolyOne
14%
Latin
America
3% Distribution
2012 Revenues: $4.2 Billion* 2012 Revenues: $4.2 Billion*
United
States
14% 5%
PP&S
20%Specialty
57%
Building & HealthCare
1.02
1.20
$1.20
$1.40
ha
re
End Markets* EPS Growth
Construction
14%
17%
Industrial
9%
0.27 0 21
0.79
$0.40
$0.60
$0.80
$1.00
Ad
ju
st
ed
E
ar
ni
ng
s P
er
S
Electrical &
0.12
0.21 0.13
$0.00
$0.20
2006 2007 2008 2009 2010 2011 2012
Page 10
* Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms
Specialty
U it d
2012 Revenues: $2.4 Billion* Solutions
United
States
59%
9%
Latin
America
Building &
C t ti
HealthCare
o
f S
al
es
12-16%
End Markets* Expanding Profits
Construction
Electrical &
Industrial
15%
1.5%
3.2% 4.3%
5.3%
8.4% 9.1%
O
pe
ra
tin
g
In
co
m
e
Page 11
2006 2007 2008 2009 2010 2011 2012 2015
O
Target* Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms
Designed Structures and Solutions
United States
2012 Revenues: $0.85 Billion* Solutions
84%
Latin America
4% Building & Construction
Sign & Advertising
3%
Recreation & Leisure
Pool & Spa
1%
Distribution &
Thermoform
2% Operating Income % of Sales
2012 Revenue by Industry Segment* Expanding Profits**
Electrical & Electronics
23%Industrial
3%
2.2%
8 ‐ 10%
1%
HealthCare
2012 2015
Target
Page 12
*Pro Forma includes FY2012 results for Spartech (11/03/12 YE)
**Pro Forma results include Spartech corporate allocations for FY12
Positioned for Earnings Growth
2015 Target
Rev: $5B
Adj.
https://www.avient.com/resource-center?document_type=59&page=25
Avient Resources
Avient Resources
Color and Additive Masterbatches for the Electrical and Electronics Industry
https://www.avient.com/resource-center?document_type=59&document_subtype=0&industry=0&product_family=0&product_name=0&op=FILTER RESULTS&form_id=resource_filter_form&page=25
Avient Resources
Avient Resources
Color and Additive Masterbatches for the Electrical and Electronics Industry
https://www.avient.com/resource-center?document_subtype=0&document_type=59&form_id=resource_filter_form&industry=0&op=FILTER RESULTS&product_family=0&product_name=0&page=25
Avient Resources
Avient Resources
Color and Additive Masterbatches for the Electrical and Electronics Industry
https://www.avient.com/sites/default/files/2022-02/Avient Design Overview Brochure.pdf
AVIENT DESIGN
FRESH THINKING
SMARTER DESIGNS
ADVANCED MATERIALS
OEMS TURN TO AVIENT DESIGN WHEN THEY ARE LAUNCHING A NEW PRODUCT,
OR WHEN THEY WANT TO IMPROVE AN EXISTING PRODUCT.
WHO
WHERE
WHY
WHEN
The best time to involve Avient Design?
You
have the responsibility to conduct full-scale end-product performance testing to determine suitability in your application, and you assume all risk and liability arising from your use of the
information and/or use or handling of any product.
https://www.avient.com/sites/default/files/2022-12/Mevopur Colors for Ophthalmic Closures Application Bulletin_A4.pdf
Custom
pre-colored formulations can be developed in other
resins upon customer request.
Copyright © 2022, Avient Corporation.
You have the responsibility to conduct full-scale end-product performance testing to determine
suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.